Literature DB >> 33273858

MicroRNA-200c Nanoparticles Sensitized Gastric Cancer Cells to Radiotherapy by Regulating PD-L1 Expression and EMT.

Lingyu Qian1,2, Fangcen Liu3, Yanhong Chu1, Qingqing Zhai1, Xiao Wei3, Jie Shao1, Rutian Li1, Qiuping Xu1, Lixia Yu1, Baorui Liu1, Qin Liu1.   

Abstract

INTRODUCTION: Immuno-checkpoint inhibitors (ICIs) in advanced gastric cancer either as monotherapy or in combining strategies are rapidly evolving but still in early phase. Various efforts have been made to provide insights into regulating immune checkpoint molecule programmed cell death ligand-1 (PD-L1) expression to improve ICIs efficacy. The aim of this study was to investigate the effect and potential mechanism of miR-200c nanoparticles combined with radiotherapy in gastric cancer cells.
METHODS: We prepared miR-200c-loaded nanoparticles (miR-200c NPs) to achieve targeted delivery of miR-200c to AGS cells. The roles of miR-200c NPs and radiotherapy in regulating the viability of AGS cells were assessed by CCK-8 toxicity test and Annexin V-FITC/PI apoptosis kit. Flow cytometry was used to analyze expression of PD-L1 and CD44 on the surface of AGS cells treated by miR-200c NPs and/or ionizing radiation. Enzyme-linked immunosorbent assay (ELISA) was used to test the level of transforming growth factor-beta 1 (TGF-β1) secreted by AGS cells. The cooperation mechanism between miR-200c NPs and radiotherapy was also explored in vitro.
RESULTS: Compared with naked miR-200c mimics, miR-200c NPs significantly downregulated PD-L1 expression of gastric cancer cells. The combination of miR-200c NPs and radiotherapy showed significantly synergistic inhibitory effect on gastric cancer cells by inhibiting immune escape mediated by PD-L1, reversing EMT phenotype as well as abrogating cancer stem cells (CSCs)-associated properties of tumor cells.
CONCLUSION: MiR-200c NPs sensitized gastric cancer cells to radiotherapy by regulating PD-L1 expression and EMT.
© 2020 Qian et al.

Entities:  

Keywords:  PD-L1; gastric cancer; microRNA-200c; nanoparticle; radiotherapy

Year:  2020        PMID: 33273858      PMCID: PMC7707438          DOI: 10.2147/CMAR.S279978

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


  36 in total

1.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

2.  Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing.

Authors:  Lin-Lin Sun; Ri-Yao Yang; Chia-Wei Li; Mei-Kuang Chen; Bin Shao; Jung-Mao Hsu; Li-Chuan Chan; Yi Yang; Jennifer L Hsu; Yun-Ju Lai; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2018-07-01       Impact factor: 6.166

3.  Synergistic effects of CD44 and TGF-β1 through AKT/GSK-3β/β-catenin signaling during epithelial-mesenchymal transition in liver cancer cells.

Authors:  Na Ri Park; Jung Hoon Cha; Jeong Won Jang; Si Hyun Bae; Bohyun Jang; Jung-Hee Kim; Wonhee Hur; Jong Young Choi; Seung Kew Yoon
Journal:  Biochem Biophys Res Commun       Date:  2016-06-16       Impact factor: 3.575

4.  E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells.

Authors:  Guido Lammering; Marc Vooijs; Jan Theys; Barry Jutten; Roger Habets; Kim Paesmans; Arjan J Groot; Philippe Lambin; Brad G Wouters
Journal:  Radiother Oncol       Date:  2011-06-15       Impact factor: 6.280

5.  Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

Authors:  Encouse B Golden; Arpit Chhabra; Abraham Chachoua; Sylvia Adams; Martin Donach; Maria Fenton-Kerimian; Kent Friedman; Fabio Ponzo; James S Babb; Judith Goldberg; Sandra Demaria; Silvia C Formenti
Journal:  Lancet Oncol       Date:  2015-06-18       Impact factor: 41.316

Review 6.  Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology.

Authors:  Robert G Bristow; Brian Alexander; Michael Baumann; Scott V Bratman; J Martin Brown; Kevin Camphausen; Peter Choyke; Deborah Citrin; Joseph N Contessa; Adam Dicker; David G Kirsch; Mechthild Krause; Quynh-Thu Le; Michael Milosevic; Zachary S Morris; Jann N Sarkaria; Paul M Sondel; Phuoc T Tran; George D Wilson; Henning Willers; Rebecca K S Wong; Paul M Harari
Journal:  Lancet Oncol       Date:  2018-05       Impact factor: 41.316

7.  Matrix rigidity regulates a switch between TGF-β1-induced apoptosis and epithelial-mesenchymal transition.

Authors:  Jennifer L Leight; Michele A Wozniak; Sophia Chen; Michelle L Lynch; Christopher S Chen
Journal:  Mol Biol Cell       Date:  2012-01-11       Impact factor: 4.138

8.  Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Authors:  Christina Twyman-Saint Victor; Andrew J Rech; Amit Maity; Ramesh Rengan; Kristen E Pauken; Erietta Stelekati; Joseph L Benci; Bihui Xu; Hannah Dada; Pamela M Odorizzi; Ramin S Herati; Kathleen D Mansfield; Dana Patsch; Ravi K Amaravadi; Lynn M Schuchter; Hemant Ishwaran; Rosemarie Mick; Daniel A Pryma; Xiaowei Xu; Michael D Feldman; Tara C Gangadhar; Stephen M Hahn; E John Wherry; Robert H Vonderheide; Andy J Minn
Journal:  Nature       Date:  2015-03-09       Impact factor: 49.962

Review 9.  TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis.

Authors:  Yang Hao; David Baker; Peter Ten Dijke
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

10.  Akt promotes endocardial-mesenchyme transition.

Authors:  Kafi N Meadows; Seema Iyer; Mark V Stevens; Duanning Wang; Sharon Shechter; Carole Perruzzi; Todd D Camenisch; Laura E Benjamin
Journal:  J Angiogenes Res       Date:  2009-09-21
View more
  6 in total

1.  CircPRDM2 Contributes to Doxorubicin Resistance of Osteosarcoma by Elevating EZH2 via Sponging miR-760.

Authors:  Jianjun Yuan; Yan Liu; Quan Zhang; Zhishuai Ren; Guang Li; Rong Tian
Journal:  Cancer Manag Res       Date:  2021-06-02       Impact factor: 3.989

2.  LncRNA OGFRP1 promotes cell proliferation and suppresses cell radiosensitivity in gastric cancer by targeting the miR-149-5p/MAP3K3 axis.

Authors:  Huihao Qin; Xing Li; Wei Zhang; Zhiqiang Ding
Journal:  J Mol Histol       Date:  2022-01-20       Impact factor: 2.611

Review 3.  Roles of microRNAs in Gastrointestinal Cancer Stem Cell Resistance and Therapeutic Development.

Authors:  Ga-Ram Hwang; John G Yuen; Jingfang Ju
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

Review 4.  Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology.

Authors:  Tuan Hiep Tran; Thi Thu Phuong Tran
Journal:  R Soc Open Sci       Date:  2022-04-13       Impact factor: 2.963

Review 5.  The Features of Immune Checkpoint Gene Regulation by microRNA in Cancer.

Authors:  Fatimat Kipkeeva; Tatyana Muzaffarova; Alexandra Korotaeva; Danzan Mansorunov; Pavel Apanovich; Maxim Nikulin; Olga Malikhova; Ivan Stilidi; Alexander Karpukhin
Journal:  Int J Mol Sci       Date:  2022-08-18       Impact factor: 6.208

Review 6.  Nanotechnology in Immunotherapy for Type 1 Diabetes: Promising Innovations and Future Advances.

Authors:  Saumya Nigam; Jack Owen Bishop; Hanaan Hayat; Tahnia Quadri; Hasaan Hayat; Ping Wang
Journal:  Pharmaceutics       Date:  2022-03-15       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.